{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:29:52Z","timestamp":1790803792847,"version":"4.1.0"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lamotrigine (LMT) is a phenyltriazine derivative that was originally described as an antiepileptic drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This literature review aims to evaluate the clinical epidemiological profile, pathological mechanisms, and management of lamotrigine-associated movement disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Relevant reports in six databases were identified and assessed by two reviewers without language restriction. Reports that the individuals only developed tremor or ataxia after LMT use were not included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total 48 reports of 108 cases from 19 countries were assessed. The movement disorders associated with LMT found were 29 tics, 21 dyskinesias, 14 myoclonus, 13 parkinsonism, 10 dystonia, and 1 stuttering. The not clearly defined cases included 10 akathisia, 4 myoclonus, 4 cerebellar syndromes, 1 hypertonia, 1 dyskinesia, and an unknown number of dystonia cases. The mean reported age was 33.34 years (range: 1.574 years). The male was the predominant sex and the most common LMT indication was epilepsy. The mean LMT-dose at the movement disorder onset was 228 mg. The time from LMT start to the onset of movement disorder was within 6 months in 81%. The time from LMT withdrawal to complete recovery was within 1 month in 83%. The most common management was LMT withdrawal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In the literature, the majority of the cases did not give a clear picture of the individual, and the times of movement disorder onset and recovery are not described. We believe that before withdrawal LMT, a dose adjustment based on the benefits and adverse events with careful evaluation case-by-case can be done.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0028-3886.333440","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T01:47:50Z","timestamp":1640656070000},"page":"1524-1538","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Lamotrigine-Associated Movement Disorder"],"prefix":"10.4103","volume":"69","author":[{"given":"Jamir Pitton","family":"Rissardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L Fornari","family":"Caprara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-4-20240907","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1111\/j.1528-1157.1991.tb05883.x","article-title":"Clinical pharmacology of lamotrigine","volume":"32","author":"Peck","year":"1991","journal-title":"Epilepsia"},{"key":"R3-4-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2007.09.012","article-title":"Discovery and development of lamotrigine for bipolar disorder: Astory of serendipity, clinical observations, risk taking, and persistence","volume":"108","author":"Weisler","year":"2008","journal-title":"J Affect Disord"},{"key":"R5-4-20240907","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/S0149-2918(03)80314-4","article-title":"Newer antiepileptic drugs: Possible uses in the treatment of neuropathic pain and migraine","volume":"25","author":"Pappagallo","year":"2003","journal-title":"Clin Ther"},{"key":"R6-4-20240907","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0028-3908(01)00198-8","article-title":"Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: Implications for its effects in seizure and affective disorders","volume":"42","author":"Braga","year":"2002","journal-title":"Neuropharmacology"},{"key":"R7-4-20240907","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fnbeh.2014.00189","article-title":"A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy","volume":"8","author":"Coplan","year":"2014","journal-title":"Front Behav Neurosci"},{"key":"R8-4-20240907","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R9-4-20240907","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bcp.2011.12.032","article-title":"Lamotrigine is a substrate for OCT1 in brain endothelial cells","volume":"83","author":"Dickens","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"R10-4-20240907","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","article-title":"The transport of antiepileptic drugs by P-glycoprotein","volume":"64","author":"Zhang","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"R12-4-20240907","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1528-1157.1986.tb03536.x","article-title":"Acute effects of lamotrigine (BW430C) in persons with epilepsy","volume":"27","author":"Binnie","year":"1986","journal-title":"Epilepsia"},{"key":"R15-4-20240907","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R16-4-20240907","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1017\/pan.2018.26","article-title":"No longer lost in translation: Evidence that Google Translate works for comparative bag-of-words text applications","volume":"26","author":"De Vries","year":"2018","journal-title":"Polit Anal"},{"key":"R17-4-20240907","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/WNF.0000000000000020","article-title":"Generalized myoclonus and spasticity induced by lamotrigine toxicity: Acase report and literature review","volume":"37","author":"Algahtani","year":"2014","journal-title":"Clin Neuropharmacol"},{"key":"R18-4-20240907","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.pnpbp.2007.04.015","article-title":"Co-occurence of blepharospasm, tourettism and obsessive-compulsive symptoms during lamotrigine treatment","volume":"31","author":"Alkin","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R19-4-20240907","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)80120-5","article-title":"Self-poisoning with lamotrigine","volume":"342","author":"Buckley","year":"1993","journal-title":"Lancet"},{"key":"R20-4-20240907","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1399-5618.2011.00974.x","article-title":"Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): Arandomized, multicenter, double-blind study (CN138-392)","volume":"14","author":"Carlson","year":"2012","journal-title":"Bipolar Disord"},{"key":"R21-4-20240907","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/j.1528-1157.1999.tb02053.x","article-title":"Paradoxic reaction to lamotrigine in a child with benign focal epilepsy of childhood with centrotemporal spikes","volume":"40","author":"Catania","year":"1999","journal-title":"Epilepsia"},{"key":"R22-4-20240907","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/1574886311207040269","article-title":"Lamotrigine induced whole body tics: A case report and literature review","volume":"11","author":"Centorino","year":"2016","journal-title":"Curr Drug Saf"},{"key":"R23-4-20240907","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1212\/01.WNL.0000130195.62670.A6","article-title":"Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy","volume":"63","author":"Cerminara","year":"2004","journal-title":"Neurology"},{"key":"R25-4-20240907","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/JCP.0b013e318167465f","article-title":"Myoclonus provoked by lamotrigine in a bipolar patient","volume":"28","author":"Corcuera","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R26-4-20240907","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/01.wnl.0000174517.21383.36","article-title":"Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies","volume":"65","author":"Crespel","year":"2005","journal-title":"Neurology"},{"key":"R27-4-20240907","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/08830738030180070301","article-title":"Unusual side effects of lamotrigine therapy","volume":"18","author":"Das","year":"2003","journal-title":"J Child Neurol"},{"key":"R28-4-20240907","first-page":"39","article-title":"Dopa-responsive dystonia subsequent tolamotrigine administration","volume":"12","author":"Ebrahimi","year":"2013","journal-title":"Iran J Pharmacol Ther"},{"key":"R30-4-20240907","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s13181-012-0210-x","article-title":"Case files of the University of California San Francisco Medical Toxicology Fellowship: Lamotrigine toxicity","volume":"8","author":"Fleurat","year":"2012","journal-title":"J Med Toxicol"},{"key":"R31-4-20240907","first-page":"32","article-title":"Movement disorder associated with lamotrigine treatment in children and adolescents","volume":"37","author":"Frost","year":"1996","journal-title":"Epilepsia"},{"key":"R32-4-20240907","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.braindev.2016.11.003","article-title":"Massive lamotrigine poisoning. A case report","volume":"39","author":"Grosso","year":"2017","journal-title":"Brain Dev"},{"key":"R33-4-20240907","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0387-7604(99)00048-0","article-title":"Myoclonic status epilepticus following high-dosage lamotrigine therapy","volume":"21","author":"Guerrini","year":"1999","journal-title":"Brain Dev"},{"key":"R35-4-20240907","first-page":"1289","article-title":"Report of severe menorrhagia following the maximum amount of lamotrigine overdose","volume":"14","author":"Hajiali","year":"2015","journal-title":"Iran J Pharm Res"},{"key":"R37-4-20240907","doi-asserted-by":"crossref","first-page":"17m02231","DOI":"10.4088\/PCC.17m02231","article-title":"Lamotrigine rechallenge in treatment-resistant bipolar disorder","volume":"20","author":"Inaba","year":"2018","journal-title":"Prim Care Companion CNS Disord"},{"key":"R38-4-20240907","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00002826-200003000-00005","article-title":"Disabling erratic myoclonus during lamotrigine therapy with high serum level--report of two cases","volume":"23","author":"Janszky","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"R39-4-20240907","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.pediatrneurol.2004.01.005","article-title":"Chorea as manifestation of epilepsia partialis continua in a child","volume":"31","author":"Kankirawatana","year":"2004","journal-title":"Pediatr Neurol"},{"key":"R40-4-20240907","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1017\/S1092852900020617","article-title":"An association of intrusive, repetitive phrases with lamotrigine treatment in bipolar II disorder","volume":"12","author":"Kemp","year":"2007","journal-title":"CNS Spectr"},{"key":"R41-4-20240907","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3988\/jcn.2007.3.2.93","article-title":"A case of lamotrigine-induced excessive involuntary eye blinking","volume":"3","author":"Kim","year":"2007","journal-title":"JClin Neurol (Seoul, Korea"},{"key":"R42-4-20240907","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.52.6.1191","article-title":"Lamotrigine-induced tourettism","volume":"52","author":"Lombroso","year":"1999","journal-title":"Neurology"},{"key":"R43-4-20240907","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1089\/cap.2013.0057","article-title":"Lamotrigine-induced facial tic in a pediatric bipolar disorder patient","volume":"23","author":"Lu","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R44-4-20240907","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/18715249113136660060","article-title":"Dystonia associated with lamotrigine therapy: Acase report and review of the literature","volume":"9","author":"Marrero-Gonzalez","year":"2014","journal-title":"Curr Drug Saf"},{"key":"R46-4-20240907","first-page":"499","article-title":"Choreatic dyskinesia following lamotrigine overdose","volume":"39","author":"Miller","year":"2001","journal-title":"J Toxicol Clin Toxicol"},{"key":"R47-4-20240907","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0883073807308693","article-title":"Choreiform dyskinesia following isolated lamotrigine overdose","volume":"23","author":"Miller","year":"2008","journal-title":"J Child Neurol"},{"key":"R48-4-20240907","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/15563650.2013.818685","article-title":"A case series of patients with lamotrigine toxicity at one center from 2003 to 2012","volume":"51","author":"Moore","year":"2013","journal-title":"Clin Toxicol (Phila"},{"key":"R49-4-20240907","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1590\/S1676-26492007000400008","article-title":"Late side-effects of valproate and lamotrigine","volume":"13","author":"Moreira","year":"2007","journal-title":"J Epilepsy Clin Neurophysiol"},{"key":"R50-4-20240907","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/mds.23120","article-title":"Facial tic associated with lamotrigine in adults","volume":"25","author":"Musiek","year":"2010","journal-title":"Mov Disord"},{"key":"R51-4-20240907","first-page":"1","article-title":"Seizure, dystonia or something else? - Case report","volume":"2015","author":"Rajda CW","year":"2015","journal-title":"Controversies Neurol"},{"key":"R52-4-20240907","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/01.jcp.0000219927.49799.c0","article-title":"Combination therapy of lamotrigine and escitalopram may cause myoclonus","volume":"26","author":"Rosenhagen","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R53-4-20240907","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/j.1468-1331.2010.02981.x","article-title":"Lamotrigine induced dyskinesia in Parkinson's disease","volume":"17","author":"Sabolek","year":"2010","journal-title":"Eur J Neurol"},{"key":"R54-4-20240907","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/mds.21125","article-title":"Parkinsonism due to lamotrigine","volume":"21","author":"Santens","year":"2006","journal-title":"Mov Disord"},{"key":"R55-4-20240907","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1176\/appi.ajp.163.1.159","article-title":"Tourette's symptoms provoked by lamotrigine in a bipolar patient","volume":"163","author":"Seem\u00fcller","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R56-4-20240907","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1212\/WNL.48.5.1282","article-title":"Lamotrigine trial in idiopathic parkinsonism: Adouble-blind, placebo-controlled, crossover study","volume":"48","author":"Shinotoh","year":"1997","journal-title":"Neurology"},{"key":"R57-4-20240907","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1528-1157.2000.tb00254.x","article-title":"Lamotrigine-induced tic disorder: Report of five pediatric cases","volume":"41","author":"Sotero de Menezes","year":"2000","journal-title":"Epilepsia"},{"key":"R58-4-20240907","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2016.12.022","article-title":"De novo multifocal myoclonus induced by lamotrigine in a temporal lobe epilepsy case","volume":"373","author":"Tombini","year":"2017","journal-title":"J Neurol Sci"},{"key":"R59-4-20240907","first-page":"1361","article-title":"Sydenham's-like picture and tourettism as related to lamotrigine toxicity","volume":"45","author":"Vance","year":"2004","journal-title":"Epilepsia"},{"key":"R60-4-20240907","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1592\/phco.19.10.877.31554","article-title":"Lamotrigine-induced blepharospasm","volume":"19","author":"Verma","year":"1999","journal-title":"Pharmacotherapy"},{"key":"R61-4-20240907","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/mds.21585","article-title":"Lamotrigine-induced bilateral ballism","volume":"22","author":"Yetimalar","year":"2007","journal-title":"Mov Disord"},{"key":"R62-4-20240907","first-page":"147","article-title":"Movement disorders in patients taking anticonvulsants","volume":"78","author":"Zadikoff","year":"2007","journal-title":"JNeurolNeurosurgPsychiatry"},{"key":"R63-4-20240907","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/08830738060210041301","article-title":"Chorea induced by lamotrigine","volume":"21","author":"Zesiewicz","year":"2006","journal-title":"J Child Neurol"},{"key":"R64-4-20240907","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF02251231","article-title":"Lamotrigine in Parkinson's disease--Adouble blind study","volume":"10","author":"Zipp","year":"1995","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"R68-4-20240907","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00002018-199818040-00004","article-title":"Safety review of adult clinical trial experience with lamotrigine","volume":"18","author":"Messenheimer","year":"1998","journal-title":"Drug Saf"},{"key":"R69-4-20240907","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0014-2999(94)00493-5","article-title":"The novel antiepileptic drug, lamotrigine, exerts prodystonic effects in a mutant hamster model of generalized dystonia","volume":"264","author":"Richter","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"R70-4-20240907","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0006-8993(87)91436-3","article-title":"GABA and dopamine interaction in the basal ganglia: Dopaminergic supersensitivity following chronic elevation of brain gamma-aminobutyric acid levels","volume":"412","author":"Sivam","year":"1987","journal-title":"Brain Res"},{"key":"R71-4-20240907","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/S0028-3908(00)00051-4","article-title":"The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro","volume":"39","author":"Cunningham","year":"2000","journal-title":"Neuropharmacology"},{"key":"R72-4-20240907","first-page":"69","article-title":"The effect of central nervous system stimulants on Tourette syndrome","volume":"2","author":"Golden","year":"1977","journal-title":"AnnNeurol"},{"key":"R74-4-20240907","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","article-title":"The functional anatomy of basal ganglia disorders","volume":"12","author":"Albin","year":"1989","journal-title":"Trends Neurosci"},{"key":"R75-4-20240907","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0006-8993(96)00915-8","article-title":"A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome","volume":"741","author":"Gerlach","year":"1996","journal-title":"Brain Res"},{"key":"R76-4-20240907","first-page":"123","article-title":"Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome","volume":"58","author":"Anderson","year":"1992","journal-title":"Adv Neurol"},{"key":"R77-4-20240907","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/15622970701332520","article-title":"Lamotrigine in motor and mood symptoms of Huntington's disease","volume":"9","author":"Shen","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"R78-4-20240907","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4088\/JCP.09r05268yel","article-title":"Antipsychotic medication and oxidative cell stress: Asystematic review","volume":"72","author":"Lepping","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"R79-4-20240907","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archpsyc.1995.03950160008002","article-title":"Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics","volume":"52","author":"Akbarian","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"R80-4-20240907","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clinph.2015.08.009","article-title":"Myoclonus in the critically ill: Diagnosis, management, and clinical impact","volume":"127","author":"Sutter","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"R81-4-20240907","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0079-6123(06)61013-3","article-title":"Sodium channel expression and the molecular pathophysiology of pain after SCI","volume":"161","author":"Hains","year":"2007","journal-title":"Prog Brain Res"},{"key":"R82-4-20240907","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1528-1167.2010.02640.x","article-title":"Sodium channel SCN1A and epilepsy: Mutations and mechanisms","volume":"51","author":"Escayg","year":"2010","journal-title":"Epilepsia"},{"key":"R83-4-20240907","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson's disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J Neural Transm (Vienna"},{"key":"R84-4-20240907","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1017\/S0317167100020904","article-title":"Lamotrigine--An update","volume":"23","author":"Brodie","year":"1996","journal-title":"Can J Neurol Sci"},{"key":"R85-4-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(96)00134-3","article-title":"Motor effects of lamotrigine in naive and dopamine-depleted mice","volume":"304","author":"Kaur","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"R86-4-20240907","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0024-3205(97)00981-8","article-title":"Lamotrigine inhibits the in situ activity of tyrosine hydroxylase in striatum of audiogenic seizure-prone and audiogenic seizure-resistant Balb\/c mice","volume":"61","author":"Vriend","year":"1997","journal-title":"Life Sci"},{"key":"R87-4-20240907","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.bjp.0705737","article-title":"Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat","volume":"142","author":"Ahmad","year":"2004","journal-title":"Br J Pharmacol"},{"key":"R88-4-20240907","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1345\/aph.1E192","article-title":"Evaluation of lamotrigine toxicity reported to poison centers","volume":"38","author":"Lofton","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R89-4-20240907","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1528-1157.1986.tb03572.x","article-title":"Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats","volume":"27","author":"Miller","year":"1986","journal-title":"Epilepsia"},{"key":"R90-4-20240907","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3940(91)90056-Y","article-title":"Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia","volume":"133","author":"Richter","year":"1991","journal-title":"Neurosci Lett"},{"key":"R91-4-20240907","first-page":"703","article-title":"Dystonia after striatopallidal and thalamic stroke: Clinicoradiological correlations and pathophysiological mechanisms","volume":"65","author":"Krystkowiak","year":"1998","journal-title":"JNeurolNeurosurgPsychiatry"},{"key":"R92-4-20240907","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/AOMD.AOMD_22_19","article-title":"Comment: Dystonia and asterixis in acute thalamic infarct: Proposed mechanism","volume":"2","author":"Pitton Rissardo","year":"2019","journal-title":"Ann Mov Disord"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.333440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:52:23Z","timestamp":1787755943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.333440"}},"subtitle":["A Literature Review"],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/0028-3886.333440","relation":{},"ISSN":["0028-3886"],"issn-type":[{"value":"0028-3886","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}